Dr. Ann E. Dahlberg
Claim this profileFred Hutch/University of Washington Cancer Consortium
Studies Chronic Myelogenous Leukemia
Studies T-Lymphoblastic Leukemia/Lymphoma
5 reported clinical trials
9 drugs studied
Area of expertise
1Chronic Myelogenous Leukemia
Stage I
Stage II
2T-Lymphoblastic Leukemia/Lymphoma
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Ann E. Dahlberg is currently running
Cord Blood Transplant + Chemo
for Blood Cancers
This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic diseases. Giving chemotherapy, such as cyclophosphamide, fludarabine and thiotepa, and TBI before a donor cord blood transplant (CBT) helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after transplant may stop this from happening in patients with high-risk hematologic diseases.
Recruiting1 award Phase 2
Unlicensed Cord Blood Transplant
for Blood/Immune System Disorders
This trial is testing the safety of giving patients special blood from umbilical cords. The study focuses on patients who receive these infusions to see if there are any serious side effects. The cord blood has special cells that can help make new blood cells in the body. Umbilical cord blood has been used in the treatment of various diseases for many years, including leukemia, lymphoma, and congenital immunodeficiency.
Recruiting1 award Phase 21 criteria
More about Ann E. Dahlberg
Clinical Trial Related1 year of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Ann E. Dahlberg has experience with
- Cyclophosphamide
- Fludarabine
- Total-Body Irradiation
- Umbilical Cord Blood Transplantation
- Unlicensed CBU
- Unlicensed Cryopreserved Cord Blood Units
Breakdown of trials Ann E. Dahlberg has run
Chronic Myelogenous Leukemia
T-Lymphoblastic Leukemia/Lymphoma
Myeloid Leukemia
Acute Lymphoblastic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ann E. Dahlberg specialize in?
Ann E. Dahlberg focuses on Chronic Myelogenous Leukemia and T-Lymphoblastic Leukemia/Lymphoma. In particular, much of their work with Chronic Myelogenous Leukemia has involved Stage I patients, or patients who are Stage II.
Is Ann E. Dahlberg currently recruiting for clinical trials?
Yes, Ann E. Dahlberg is currently recruiting for 2 clinical trials in Seattle Washington. If you're interested in participating, you should apply.
Are there any treatments that Ann E. Dahlberg has studied deeply?
Yes, Ann E. Dahlberg has studied treatments such as Cyclophosphamide, Fludarabine, Total-Body Irradiation.
What is the best way to schedule an appointment with Ann E. Dahlberg?
Apply for one of the trials that Ann E. Dahlberg is conducting.
What is the office address of Ann E. Dahlberg?
The office of Ann E. Dahlberg is located at: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington 98109 United States. This is the address for their practice at the Fred Hutch/University of Washington Cancer Consortium.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.